Loading
Larimar Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 08 Jul 2026.
Larimar Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Larimar Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 9 insiders have disclosed 10 filings since 18 October 2025.
Every open-market trade in the period is a purchase: 5 purchases worth €5.2M, from 4 insiders, and not a single sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. One trade stands out by size: a purchase of €4.6M from Flynn James E, disclosed on 2 March 2026. The buyers include 4 senior executives.
With 10 filings in twelve months, the company is quieter than the median of 22 filings across the 5,458 companies we follow on the same exchange. The full history, which starts in 2016, counts 28 purchases against no sales.
In all, 4 purchases were made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The latest purchase dates back some time: it was published 102 days ago, on 8 July 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
47
Thresholds
n/a
Buy Volume
€39M
28 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleJames E. Flynn2 buys
Thomas Edward Hamilton2 buys
Frank E. Thomas1 buy
Jeffrey W. Sherman1 buy
Since the insiders bought
- -51.9%Entry US$4.13 · Close 16 Oct 2026 US$1.99
- -36.3%Entry US$5.51 · Close at T+90 US$3.51
- -36.3%Entry US$5.51 · Close at T+90 US$3.51
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Larimar Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$14.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.99
Analyst consensus
10 analystsStrong buy
US$5.00Target US$14.40(+625%)US$26.00
Income statement
EBITDA-US$172.1M
Net income-US$165.7M0.0% margin
Valuation
PER (forward)-1.9x
P/Book1.6x
Beta0.69
Balance sheet & cash
Market capUS$206.2M
Total debtUS$4.1M
Free Cash Flow-US$113.3M
Debt / Equity4%
Profitability & ownership
ROE-139.6%
ROA-71.0%
% insiders1.2%
% institutions93.7%
Last declaration on 1 October 2026
Declarations47 total
50,000 shares0Common StockSEC:0001193125-26-410719:0
50,000 shares@ US$3.33780.041% mcap5.9% of flowCommon StockSEC:0001193125-26-298523:0
Canonical exit: 4 Oct 2026 (T+90)
5,000 shares@ US$5.00100.0% of flowCommon StockSEC:0001193125-26-085510:0
Canonical exit: 28 May 2026 (T+90)
1,084,010 shares@ US$5.0012.7% of flowCommon StockSEC:0001193805-26-000205:0
Canonical exit: 28 May 2026 (T+90)
100,000 shares@ US$5.0017.3% of flowCommon StockSEC:0001193125-26-085515:0
Canonical exit: 28 May 2026 (T+90)
5,000 shares@ US$5.0050.8% of flowCommon StockSEC:0001193125-26-085514:0
Canonical exit: 28 May 2026 (T+90)
100,100 shares0Common StockSEC:0001193125-26-024826:0
25,637 shares0Common StockSEC:0001193125-26-024833:0
25,637 shares0Common StockSEC:0001193125-26-024832:0
37,604 shares0Common StockSEC:0001193125-26-024824:0
3,387,529 shares@ US$3.2026.3% of flowCommon StockSEC:0001193805-25-001155:0
Canonical exit: 29 Oct 2025 (T+90)
34,185 shares0Common StockSEC:0001062993-25-001077:0
23,306 shares0Common StockSEC:0001062993-25-001080:0
91,000 shares0Common StockSEC:0001062993-25-001078:0
23,306 shares0Common StockSEC:0001062993-25-001079:0
57,208 shares@ US$8.7418.9% of flowCommon StockSEC:0001062993-24-011568:0
Canonical exit: 16 May 2024 (T+90)
1,430,206 shares@ US$8.7432.1% of flowCommon StockSEC:0001193805-24-000245:0
Canonical exit: 16 May 2024 (T+90)
2,000 shares@ US$11.0049.2% of flowCommon StockSEC:0001062993-24-003312:0
Canonical exit: 14 May 2024 (T+90)
22,500 shares0Common StockSEC:0001062993-24-001086:0
22,500 shares0Common StockSEC:0001062993-24-001084:0
31,250 shares0Common StockSEC:0001062993-24-001085:0
66,125 shares0Common StockSEC:0001062993-24-001083:0
5,000 shares@ US$3.7323100.0% of flowCommon StockSEC:0001062993-23-022200:0
Canonical exit: 6 Mar 2024 (T+90)
2,750 shares@ US$3.73100.0% of flowCommon StockSEC:0001062993-23-011545:0
Canonical exit: 15 Aug 2023 (T+90)
5,000 shares@ US$3.726314.7% of flowCommon StockSEC:0001062993-23-011547:0
Canonical exit: 15 Aug 2023 (T+90)
25 of 47 declarations
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a U.S.-listed clinical-stage biotechnology company traded on the NASDAQ under the ticker LRMR. The company is headquartered in Bala Cynwyd, Pennsylvania, in the Philadelphia area, and is organized in Delaware. It was founded in 2005 as Zafgen, Inc. and later became Larimar Therapeutics following a merger with Chondrial Therapeutics. Today, Larimar is positioned as a highly focused rare-disease biotech, with its strategy centered on a narrow but potentially value-creating scientific and regulatory pathway. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1374690/000119312526115878/lrmr-20251231.htm?utm_source=openai))
Larimar’s core business is the development of nomlabofusp, a frataxin replacement therapy designed for Friedreich’s ataxia (FA), a rare, progressive neurodegenerative disease with limited treatment options. The company’s scientific thesis is that restoring frataxin deficiency may address the underlying biology of the disease rather than only managing symptoms. Larimar’s historical platform has also relied on cell-penetrating peptide technology, which underpins its approach to delivering protein therapeutics to mitochondria. This makes the company a classic development-stage biotech, where the value proposition depends on clinical proof-of-concept, regulatory execution, manufacturing readiness, and eventual commercialization potential. ([larimartx.com](https://larimartx.com/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Larimar operates in a concentrated rare-disease segment where differentiation is driven by mechanism, clinical data, and regulatory positioning. The company’s lead asset has been advancing through registrational activities, and in February 2026 Larimar announced that the FDA granted nomlabofusp Breakthrough Therapy Designation for adults and children with FA. Larimar has also said that its discussions with the FDA support the use of skin frataxin as a surrogate endpoint in a planned BLA submission seeking accelerated approval, which it has guided for June 2026. Those updates are important because they suggest a clearer regulatory path, although the investment case remains highly dependent on execution and trial outcomes. ([investors.larimartx.com](https://investors.larimartx.com/news-releases/news-release-details/larimar-therapeutics-announces-fda-breakthrough-therapy?utm_source=openai))
Geographically, the company’s footprint remains primarily U.S.-based, with corporate and operational activity run from Bala Cynwyd, Pennsylvania. Larimar is not yet a commercial-stage multinational; its presence is largely clinical, regulatory, and manufacturing-preparatory rather than broad-based global sales. Recent milestones include the Breakthrough Therapy Designation, ongoing open-label study updates, data publication supporting skin as a surrogate tissue for frataxin measurement, and capital raising activity in 2025 and early 2026 to support the next development phase. For investors, LRMR is best viewed as a high-risk, high-catalyst biotech name on the NASDAQ in the United States, with upside tied to whether nomlabofusp can become a first-in-class disease-modifying therapy for FA. ([investors.larimartx.com](https://investors.larimartx.com/news-releases/news-release-details/larimar-therapeutics-announces-fda-breakthrough-therapy?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
